Powered by CARB-X: Portfolio expansion announced today!

Picture

​Dear All: CARB-X has today announced funding of 7 more companies, bringing the total funded portfolio to 17 potential new therapies (or preventatives) and 1 novel point-of-care diagnostic (see graphic above). Befitting the international nature of those of you who read my occasional notes (see map just below), there are now funded companies in 6 countries (US, UK, France, Switzerland, Ireland, and India). 

Picture

Above: Locations of recent readers of these newsletters. Darker = more readers
You can read more in the press release (and don’t miss the two interactive & clickable portfolio tables), but I think it is particularly exciting that the 7 new projects include five potential new class antibiotics for Gram-negative bacteria. These will take a long time to mature and only a few will ultimately succeed, but the therapeutic part of the portfolio now contains 10 projects that pursue a novel target and 8 that are potential novel class small molecules.  

All best wishes, –jr

PS: For those of you who miss the broadcast or don’t have a local PBS station, the FRONTLINE episode of Hunting the Nightmare Bacteria will be available for streaming at http://www.pbs.org/wgbh/frontline/ beginning sometime in the next 24h.

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog.html

Upcoming meetings of interest to the AMR community:

Share

WHO Bacterial Priority Pathogen List (PPL): 2024 update

Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO 2024 PPL. WHO’s webpage about the 2024 PPL. A PowerPoint (.pptx) deck (and there is also a .pdf version) summarizing the new PPL and all prior PPLs. 22 May 2024 post-newsletter

Environmental, Animal, and Human Uses of Phage: WHO webinars

Dear All, I have just this weekend learned of a 3-part WHO webinar series on uses of phage. Two of the webinars have already been held; the 3rd is scheduled for 16 May. All are / will be available for post-webinar review. The links you need are below — in addition, a copy of the

New UK 5-year AMR plan: Subscription model details!

Dear All, Today is a newsletter double-header! Coming hard on the heels of the opportunity to support an ESCMID petition to UNGA 2024, the UK today released the details of its next five-year action plan. Excitingly for this audience, there is an updated roadmap for the UK’s next steps in its subscription model. Here are

ESCMID’s UNGA 2024 Petition to EU Health Ministers: Sign and Send!

Dear All, During the GLG AMR (Global Leaders Group for AMR) event just before ECCMID (see the 3 May 2024 newsletter entitled “Path To UNGA 2024 As Of 3 May 24 / Events On 14-15 May (DC, NYC)” for details), ESCMID leadership announced that ESCMID had developed a petition to be sent by and from the

Scroll to Top